Peptides for Energy: What the Research Says About MOTS-c, SS-31, and NAD+

"Peptides for energy" is a booming longevity search, and three compounds dominate it — MOTS-c, SS-31, and NAD+. None is a proven energy treatment for healthy people, and the evidence ranges from preclinical (MOTS-c) to rare-disease-specific (SS-31) to "raises a molecule without the benefits" (NAD+). Here's the honest picture.

The three get bundled together because they all touch mitochondria — the cell's power plants — but they are not one category. One is a signaling peptide, one is now a prescription drug for a rare disease, and one is not a peptide at all. Grouping them under "energy peptides" hides those differences, so below each is graded on its own evidence, compared directly, and — because two of the three are sold on the gray market — paired with the honest sourcing and safety reality.

What are "energy" or "mitochondrial" peptides?

These are compounds taken in the hope of improving cellular energy by supporting mitochondria, which turn food into ATP. The three most-discussed are MOTS-c, a mitochondrial-derived peptide that activates the energy sensor AMPK; SS-31, a peptide that protects the mitochondrial membrane; and NAD+, a coenzyme central to energy production that is, technically, not a peptide at all. They work through very different mechanisms, sit at very different evidence stages, and only one — SS-31 — is an approved drug, and only for a rare disease.

A useful way to hold them apart is by role: MOTS-c is a signaler that nudges cells toward exercise-like adaptations, SS-31 is a protectant that stabilizes the mitochondrial membrane, and NAD+ is the fuel-cycle cofactor itself. All three are staples of longevity and biohacker discussion, filed under the broader immune and longevity category — but the evidence behind each is very different in both quantity and quality.

MOTS-c — the exercise-mimetic signaler

MOTS-c is a 16-amino-acid peptide encoded inside mitochondria that activates AMPK, the cell's master energy sensor — the same pathway aerobic exercise engages, which is the real basis for the "exercise mimetic" label. It acts through the folate–AICAR–AMPK pathway to influence glucose metabolism, insulin sensitivity, and aging, and in humans, muscle expression of the peptide rises in response to exercise itself — evidence that is largely preclinical and mechanistic rather than from clinical trials.

The label is easy to misread, though. "Mimics exercise" is not "replaces exercise," and the human evidence does not support that leap: MOTS-c is still, in people, interesting biology rather than established therapy, and researchers frame it as something that may amplify a training stimulus, not substitute for one. It is not approved for any use. For the full mechanism and the state of the research, see the MOTS-c science deep-dive; this guide keeps MOTS-c to its role in the comparison.

SS-31 (Elamipretide) — the mitochondrial protectant

SS-31 — known clinically as elamipretide — is a four-amino-acid cell-penetrating peptide that binds cardiolipin, a phospholipid on the inner mitochondrial membrane, stabilizing the cristae structure that houses ATP production. It is the most clinically studied of the three, and in September 2025 it earned FDA accelerated approval, under the brand name Forzinity, for Barth syndrome — an ultra-rare, life-limiting genetic disorder — to improve muscle strength in patients weighing at least 30 kg. That is the entire approval: not fatigue, not aging, not general energy.

The broader record is more sobering, and it matters for anyone eyeing SS-31 for vitality. Its major trials in common conditions — heart failure, heart attack, and primary mitochondrial myopathy — all missed their primary endpoints, a pattern that says more about the "energy for healthy people" pitch than the Barth approval does. Two further points are essential: the compound has real, if narrow, clinical value, but its benefit outside that rare disease is unproven; and the gray-market "SS-31" sold research-use-only is not pharmaceutical-grade Forzinity. The mechanism, trial history, and safety are covered in the SS-31 science deep-dive, with lab data on the SS-31 guide.

NAD+ — the metabolic cofactor

NAD+ (nicotinamide adenine dinucleotide) is not a peptide — it is a coenzyme, the primary electron carrier in mitochondrial energy production and a substrate for the sirtuin enzymes, and its levels decline with age. It is grouped with peptides in longevity circles because of that mitochondrial role, not its chemistry. Because NAD+ itself is poorly absorbed, it is usually supplemented through precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN).

Here the evidence is unusually clear, and unusually deflating. Human trials consistently show these precursors do raise NAD+ levels in blood and muscle — that part is well established. But raising the molecule has repeatedly failed to translate into function: controlled trials of NR found no improvement in muscle mitochondrial respiration, substrate use, or insulin sensitivity, leading one review to conclude that the clinical potential of NR in humans remains to be understood. The most consistent human signal is anti-inflammatory — not "energy." The NAD+ boosters deep-dive covers the NR-versus-NMN detail.

MOTS-c vs SS-31 vs NAD+ — how they compare

The three are not interchangeable. MOTS-c signals through AMPK to mimic exercise adaptations; SS-31 physically protects the mitochondrial membrane; NAD+ is the fuel-cycle coenzyme itself. On evidence, SS-31 has the most clinical data but an approval only for a rare disease; MOTS-c has a strong preclinical story with thin human data; and NAD+ precursors raise the molecule without delivering the energy benefit. None is proven to boost energy in healthy people, and none has been tested head-to-head against the others.

What the research does — and doesn't — show

Put plainly: no "energy peptide" is proven to raise energy in healthy people. MOTS-c's exercise-mimetic story is almost entirely preclinical. SS-31's one approval is for an ultra-rare disease, and its trials for common conditions mostly failed. And NAD+ precursors reliably raise NAD+ while repeatedly failing to move mitochondrial function. There are no head-to-head comparisons, and none of the three has an efficacy case for a healthy adult seeking "more energy."

The honest comparator here is not another peptide — it is exercise, which remains the most reliable way to improve mitochondrial function, and which NAD+ precursors in particular have compared unfavorably against. That is not a reason to dismiss the underlying science, which is genuinely interesting, but "biologically interesting" is not "clinically proven," and the distance between them is exactly where the marketing lives. It is worth remembering that two of these three are not even a "peptide for energy": SS-31 is a rare-disease drug, and NAD+ is not a peptide at all.

If you're considering these compounds — sourcing, safety, and verification

These three sit in three different legal buckets, and conflating them is where people get hurt. Forzinity (elamipretide) is a prescription drug for Barth syndrome; gray-market "SS-31" sold research-use-only is not that drug and is not pharmaceutical-grade. MOTS-c is an unapproved research chemical. NAD+ and NR are sold as dietary supplements. Those are not interchangeable categories, and a vendor blurring them is a warning sign.

For the research-grade compounds, the one thing a buyer actually controls is confirming the vial contains what the label says — independent HPLC purity plus mass-spectrometry identity. Peptigrity holds 10,051 independent lab tests across 426 shops (verified July 2026), with MOTS-c among the most-tested compounds on the platform, and you can compare those independent lab-test results, learn the methods at the how to test peptides hub, and follow the quality-verification framework before trusting any vendor in this gray-market category — the MOTS-c-specific checklist lives in our where to buy MOTS-c guide. On safety, SS-31's dominant trial side effect was injection-site reactions, MOTS-c's human safety is not well characterized, and NR is generally well tolerated; the cross-compound picture is in our peptide side effects overview, and the shifting rules — including SS-31's approval — in the FDA peptide regulation timeline.

Frequently Asked Questions

Do peptides actually boost energy?

No compound in this group is proven to raise energy in healthy people. MOTS-c is largely preclinical, SS-31 is approved only for a rare disease, and NAD+ precursors raise NAD+ without a measured energy benefit. For most people, exercise remains the most reliable way to improve mitochondrial function. Anyone considering these compounds should speak with a qualified clinician.

Which is best for energy — MOTS-c, SS-31, or NAD+?

None is proven for that purpose, and they act differently: MOTS-c signals exercise-like adaptations, SS-31 protects the mitochondrial membrane (and is approved only for Barth syndrome), and NAD+ is the fuel-cycle coenzyme. Because there are no head-to-head trials and no efficacy case for healthy-adult energy, any choice is experimental and best discussed with a physician.

Is SS-31 FDA-approved?

Yes — as elamipretide, brand name Forzinity, approved in September 2025, but only for Barth syndrome, a rare genetic disease. Its trials for common conditions like heart failure mostly failed their primary endpoints, and the gray-market "SS-31" sold research-use-only is not the approved drug and is not approved for energy or aging.

Is NAD+ a peptide?

No. NAD+ is a coenzyme — a dinucleotide — not a peptide. It gets grouped with peptides in longevity discussions because of its central role in mitochondrial energy metabolism, and it is usually supplemented indirectly through the precursors nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN).

Are these compounds safe and legal?

It varies by compound. Forzinity is a prescription drug; MOTS-c and gray-market SS-31 are unapproved research chemicals with limited human safety data, the most common trial side effect for SS-31 being injection-site reactions; and NAD+/NR is a generally well-tolerated supplement. None of this is medical advice, and legal status differs by country.

This article is for educational and informational purposes only and does not constitute medical advice. MOTS-c and research-use-only "SS-31" are not approved by the FDA (or equivalent regulators) for human use and are sold as research compounds; elamipretide (Forzinity) is approved only for Barth syndrome; NAD+ precursors are sold as dietary supplements. Always consult a qualified healthcare provider before using any peptide, supplement, or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.